Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
HIV Infections
Interventions
DRUG

Palifermin

Keratinocyte growth factor administered via injection

DRUG

Palifermin placebo

Keratinocyte growth factor placebo administered via injection

Trial Locations (22)

10016

NY Univ. HIV/AIDS CRS, New York

14607

Trillium Health ACTG CRS, Rochester

14642

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

21201

IHV Baltimore Treatment CRS, Baltimore

27514

Unc Aids Crs, Chapel Hill

27710

Duke Univ. Med. Ctr. Adult CRS, Durham

30308

The Ponce de Leon Ctr. CRS, Atlanta

37204

Vanderbilt Therapeutics CRS, Nashville

43210

The Ohio State University Medical Center, Columbus

44106

Case CRS, Cleveland

44109

MetroHealth CRS, Cleveland

90033

USC CRS, Los Angeles

90035

UCLA CARE Center CRS, Los Angeles

90502

Harbor-UCLA Med. Ctr. CRS, Torrance

92103

Ucsd, Avrc Crs, San Diego

94304

Stanford CRS, Palo Alto

98104

University of Washington AIDS CRS, Seattle

33136-1013

Univ. of Miami AIDS CRS, Miami

02118

Bmc Actg Crs, Boston

63108-2138

Washington U CRS, St Louis

10032-3732

Columbia P&S CRS, New York

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00376935 - Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults | Biotech Hunter | Biotech Hunter